NCT02427776View on ClinicalTrials.gov

A Trial for Evaluating Both Safety and Preliminary Efficacy of a Single Infusion of Stimulated Autologous CD4+T Cells in Patients With Relapsing- Remitting Multiple Sclerosis

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
BIOLOGICAL

Autologous CD4+T cells stimulated and expanded ex vivo by a MOG peptide modified by the introduction of a thioreductase motif into the flanking residues of the T cell epitope

1 administration comprising 5 - 50 millions of cells

Trial Locations (3)

1200

Cliniques universitaires Saint-Luc, Brussels

3000

University Hospital Leuven (Gasthuisberg), Leuven

4000

University Hospital of Liège, Liège

Sponsors

Lead Sponsor

Imcyse SA
All Listed Sponsors
lead

Imcyse SA

INDUSTRY